Timber Pharmaceuticals, Inc. – A LEO Pharma Company

Background

Founded in 2019, Timber Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for unmet needs in medical dermatology, with a particular emphasis on rare skin diseases lacking current therapeutic options. In January 2024, LEO Pharma acquired Timber Pharmaceuticals, integrating its assets to bolster LEO Pharma's portfolio in dermatology.

Key Strategic Focus

Timber Pharmaceuticals concentrates on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis (CI) and other sclerotic skin conditions. The company's lead product, TMB-001, is a topical isotretinoin formulated using Timber's patented IPEG™ delivery system, targeting moderate to severe subtypes of CI.

Financials and Funding

As of December 31, 2022, Timber Pharmaceuticals reported approximately $9.1 million in cash, which included $1.3 million raised through the sale of common stock and warrants in October 2022. In August 2022, the company completed an $8 million public offering consisting of common shares and warrants.

Pipeline Development

TMB-001: A topical isotretinoin formulated with the IPEG™ delivery system, targeting moderate to severe subtypes of CI. The pivotal Phase 3 ASCEND clinical trial commenced in June 2022, aiming to enroll over 140 patients across multiple countries.

TMB-003: A proprietary formulation of Sitaxsentan, a selective endothelin-A receptor antagonist, in preclinical development for the treatment of sclerotic skin diseases.

BPX-01 and BPX-04: Topical minocycline formulations in Phase 3 development for the treatment of inflammatory lesions of acne vulgaris and papulopustular rosacea, respectively.

Technological Platform and Innovation

Timber Pharmaceuticals utilizes its proprietary IPEG™ (Isotretinoin Polymeric Emulsion Gel) delivery system, designed to deliver isotretinoin directly to the skin, potentially reducing systemic exposure and associated side effects.

Leadership Team

John Koconis, MBA: Chairman, CEO & President.

Joseph Lucchese: Executive Vice President, CFO, Treasurer & Secretary.

Leadership Changes

In January 2024, LEO Pharma finalized the acquisition of Timber Pharmaceuticals' key assets, including TMB-001.

Competitor Profile

Market Insights and Dynamics

The global dermatology market was valued at approximately $22 billion in 2020 and is projected to reach $30 billion by 2026, growing at a CAGR of around 5.8%.

Competitor Analysis

Crown Laboratories: A global skincare company developing a portfolio of aesthetics, beauty, therapeutic, and prescription skincare products.

PruGen Pharmaceuticals: Develops, manufactures, and markets generic, prescription, and over-the-counter medications.

Novum Pharma: Provides a range of therapeutic solutions in dermatology.

Spear Pharmaceuticals: A specialty dermatology company.

Strategic Collaborations and Partnerships

Timber Pharmaceuticals has engaged in collaborations with entities like the Novartis Foundation, highlighting the need for partnerships to bolster its financial standing and research capabilities.

Operational Insights

Timber Pharmaceuticals operates in a highly regulated industry, with exposure to changes in healthcare policies that may affect drug pricing, reimbursement rates, and approval timelines.

Strategic Opportunities and Future Directions

Timber Pharmaceuticals is poised to explore international markets, particularly in regions with unmet medical needs. The global dermatology market was valued at approximately $22 billion in 2020 and is projected to reach $30 billion by 2026, growing at a CAGR of around 5.8% during this period.